

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Complete if Known	
				Application Number	10/574,575
				Filing Date	April 20, 2007
				First Named Inventor	E. CONTI
				Group Art Unit	1614
				Examiner Name	
				Confirmation No.	9296
Sheet	1	of	3	Attorney Docket Number	2021-123

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T <sup>6</sup>
		Office <sup>3</sup> Code	Number <sup>4</sup>	Kind <sup>5</sup> (if known)			
	1	WO	03/031606	A2	ASTRAZENECA AB	04-17-2003	
	2	WO	94/03427	A1	WARNER-LAMBERT COMPANY	02-17-1994	
Examiner Signature					Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code. <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is attached. AB indicates that only an English language abstract is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Complete if Known

Application Number	10/574,575
Filing Date	April 20, 2007
First Named Inventor	E. CONTI
Group Art Unit	1614
Examiner Name	
Confirmation No.	9296
Attorney Docket Number	2021-123

Sheet

2

of

3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	3	BAYLISS, R. et al., "Structural Basis of Aurora- Activation by TPX2 at the Mitotic Spindle," <i>Molecular Cell</i> , 12:851-862, Oct. 2003.	
	4	BISCHOFF, J. R. et al., "A Homologue of <i>Drosophila aurora</i> Kinase is Oncogenic and Amplified in Human Colorectal Cancers," <i>The EMBO Journal</i> , 17(11):3052-3065, 1998.	
	5	BISCHOFF, J. R. et al., "The Aurora/Plp Kinase Family: Regulators of Chromosome Segregation and Cytokinesis," <i>Cell Biology</i> , 9:454-459, Nov. 1999.	
	6	CAPDEVILLE, R. et al., "GLIVEC (STI1571, IMATINIB), A Rationally Developed, Targeted Anticancer Drug," <i>Nature Reviews</i> , 1:493-502, July 2002.	
	7	CHEETHAM, G. M. T. et al., "Crystal Structure of Aurora-2, an Oncogenic Serine/Threonine Kinase," <i>The J. of Biological Chemistry</i> , 277(45):42419-42422, Nov. 8, 2002.	
	8	DUTERTRE, S. et al., "On the Role of Aurora-A in Centrosome Function," <i>Oncogene</i> , 21:6175-6183, 2002.	
	9	EYERS, P. A. et al., "A Novel Mechanism for Activation of the Protein Kinase Aurora A," <i>Current Biology</i> , 13:691-697, Apr. 15, 2003.	
	10	GARCIA-ECHEVERRIA, C. et al., "ATP Site-Directed Competitive and Irreversible Inhibitors of Protein Kinases," <i>Med. Res. Rev.</i> 20:28-57, 2000.	
	11	HUSE, M. et al., "The Conformational Plasticity of Protein Kinases," <i>Cell</i> , 109:275-282, May 3, 2002.	
	12	KUFER, T. A. et al., "Human TPX2 is Required for Targeting Aurora-A Kinase to the Spindle," <i>The J. of Cell Biology</i> , 158(4):617-623, Aug. 19, 2002.	
	13	MUELLER, U. et al., "Development of a Technology for Automation and Miniaturization of Protein Crystallization," <i>J. of Biotechnology</i> , 85:7-14, 2001.	
	14	NOWAKOWSKI, J. et al., "Structures of the Cancer-Related Aurora-A, FAK, and EphA2 Protein Kinases from Nanovolume Crystallography," <i>Structure</i> , 10:1659-1667, Dec. 2002.	

